222 related articles for article (PubMed ID: 28063245)
1. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
Verhoef TI; Ragia G; de Boer A; Barallon R; Kolovou G; Kolovou V; Konstantinides S; Le Cessie S; Maltezos E; van der Meer FJ; Redekop WK; Remkes M; Rosendaal FR; van Schie RM; Tavridou A; Tziakas D; Wadelius M; Manolopoulos VG; Maitland-van der Zee AH;
N Engl J Med; 2013 Dec; 369(24):2304-12. PubMed ID: 24251360
[TBL] [Abstract][Full Text] [Related]
3. Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon.
Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):454-464. PubMed ID: 27992949
[TBL] [Abstract][Full Text] [Related]
4. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Stergiopoulos K; Brown DL
JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
Verhoef TI; Redekop WK; Daly AK; van Schie RM; de Boer A; Maitland-van der Zee AH
Br J Clin Pharmacol; 2014 Apr; 77(4):626-41. PubMed ID: 23919835
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics role in the safety of acenocoumarol therapy.
Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
[TBL] [Abstract][Full Text] [Related]
7. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
van Schie RM; Wessels JA; le Cessie S; de Boer A; Schalekamp T; van der Meer FJ; Verhoef TI; van Meegen E; Rosendaal FR; Maitland-van der Zee AH;
Eur Heart J; 2011 Aug; 32(15):1909-17. PubMed ID: 21636598
[TBL] [Abstract][Full Text] [Related]
8. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
van Schie RM; Babajeff AM; Schalekamp T; Wessels JA; le Cessie S; de Boer A; van der Meer FJ; van Meegen E; Verhoef TI; Rosendaal FR; Maitland-van der Zee AH;
J Thromb Haemost; 2012 May; 10(5):767-72. PubMed ID: 22409277
[TBL] [Abstract][Full Text] [Related]
10. Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study.
Cerezo-Manchado JJ; Roldán V; Corral J; Rosafalco M; Antón AI; Padilla J; Vicente V; González-Conejero R
Thromb Haemost; 2016 Jan; 115(1):117-25. PubMed ID: 26538428
[TBL] [Abstract][Full Text] [Related]
11. A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial.
Ragia G; Kolovou V; Kolovou G; Konstantinides S; Maltezos E; Tavridou A; Tziakas D; Maitland-van der Zee AH; Manolopoulos VG
Pharmacogenomics; 2017 Jan; 18(1):23-34. PubMed ID: 27967328
[TBL] [Abstract][Full Text] [Related]
12. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Stehle S; Kirchheiner J; Lazar A; Fuhr U
Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
[TBL] [Abstract][Full Text] [Related]
14. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
van Schie RM; Wadelius MI; Kamali F; Daly AK; Manolopoulos VG; de Boer A; Barallon R; Verhoef TI; Kirchheiner J; Haschke-Becher E; Briz M; Rosendaal FR; Redekop WK; Pirmohamed M; Maitland van der Zee AH
Pharmacogenomics; 2009 Oct; 10(10):1687-95. PubMed ID: 19842940
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M; Brouwers JR; Schalekamp T; Wilffert B
Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
[TBL] [Abstract][Full Text] [Related]
16. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.
van Schie RM; el Khedr N; Verhoef TI; Teichert M; Stricker BH; Hofman A; Buhre PN; Wessels JA; Schalekamp T; le Cessie S; van der Meer FJ; Rosendaal FR; de Boer A; Maitland-van der Zee AH; Visser LE
Pharmacogenomics; 2012 Aug; 13(11):1239-45. PubMed ID: 22920394
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
[TBL] [Abstract][Full Text] [Related]
18. CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.
Varnai R; Sipeky C; Nagy L; Balogh S; Melegh B
Environ Toxicol Pharmacol; 2017 Dec; 56():282-289. PubMed ID: 29055218
[TBL] [Abstract][Full Text] [Related]
19. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
20. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment.
Cerezo-Manchado JJ; Roldan V; Rosafalco M; Anton AI; Arroyo AB; Garcia-Barbera N; Martínez AB; Padilla J; Corral J; Vicente V; Gonzalez-Conejero R
Pharmacogenomics; 2014 May; 15(7):987-96. PubMed ID: 24956252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
